The impact of pemafibrate on dyslipidemia in patients with severe adult growth hormone deficiency: A prospective cohort study.
Phase 4
- Conditions
- dyslipidemia
- Registration Number
- JPRN-UMIN000038558
- Lead Sponsor
- TT EAST SAPPORO HOSPITA
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 34
Inclusion Criteria
Not provided
Exclusion Criteria
Patients who thought to be inappropriate to enter this study for some reasons by physician's judgments
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Changes of TG before and after administration of pemafibrate
- Secondary Outcome Measures
Name Time Method 1)total lipid metabolism (HDL-cholesterol, RLP-cholesterol, etc) 2)Liver function 3)Renal function 4)Body weight, Body mass index, Abdominal circumference 5)Blood pressure 6)Adverse event 7)Influencing factors and changes on lipid metabolism, liver/renal function 8)The adult hypopituitarism questionnaire score